Our development programs focus on a product portfolio of cannabinoid based medicine
Our development programs focus on a product portfolio of cannabinoid based medicines and drug delivery technologies, including the novel lipophilic compound delivery technology Alitra®.
Drug Delivery Technology Alitra®
Echo Pharmaceutical’s highly advanced drug delivery technology Alitra® offers a practical solution for administering lipophilic compounds to patients. Alitra® distinguishes itself by significantly improving the absorption of poor water soluble compounds in the human blood, presenting a favorable bioavailability and demonstrating steadier temporal profiles. Alitra® has proven to be especially useful for drugs for which low water-solubility and deterioration in the gastrointestinal system contribute to a low oral bioavailability.
The efficacy of Namisol® in patients with Multiple Sclerosis, Alzheimer’s and Chronic Pain is being researched. Additional indications are being examined. After successful completion of pre-clinical and clinical Phase I studies, Namisol® is now in Phase II of clinical development. Our research has been published.
Namisol® with Alitra® DDT - Clinical Studies
Phase I studies and presentations:
Phase II studies in MS:
Phase II studies and presentations in Dementia:
Phase II studies in Pain: